中国药房2024,Vol.35Issue(17) :2158-2164.DOI:10.6039/j.issn.1001-0408.2024.17.18

中药通过调控细胞自噬治疗支气管哮喘的研究进展

Progress on traditional Chinese medicine in the treatment of bronchial asthma by regulating autophagy

李梦茵 宋桂华 王婷婷 任明月
中国药房2024,Vol.35Issue(17) :2158-2164.DOI:10.6039/j.issn.1001-0408.2024.17.18

中药通过调控细胞自噬治疗支气管哮喘的研究进展

Progress on traditional Chinese medicine in the treatment of bronchial asthma by regulating autophagy

李梦茵 1宋桂华 2王婷婷 1任明月1
扫码查看

作者信息

  • 1. 河南中医药大学儿科医学院,郑州 450046
  • 2. 河南中医药大学第一附属医院儿科医院儿科二区,郑州 450000
  • 折叠

摘要

支气管哮喘(以下简称"哮喘")是一种以慢性气道炎症和气道重塑为主要特征的异质性气道疾病,其发病机制复杂,发病率高且病情易反复.自噬在改善哮喘症状中发挥了重要的调控作用.中药活性成分(如黄酮类化合物、蒽醌类化合物、萜类化合物等)以及中药复方(如五虎汤、平喘颗粒、三子养亲汤等)可以通过调控自噬相关蛋白及信号通路,抑制气道炎性反应、减轻气道高反应、缓解气道重塑,从而起到治疗哮喘的目的.但目前研究多为基础研究,且证据质量不高,今后应深入开展高质量的临床与基础研究,以充分论证中药通过调控自噬治疗哮喘的科学性.

Abstract

Bronchial asthma(referred to as"asthma")is a heterogeneous airway disease characterized by chronic airway inflammation and airway remodeling.Its pathogenesis is complex,the incidence is high and the disease is easy to repeat.Autophagy plays an important regulatory role in improving asthma symptoms.By regulating autophagy-related proteins and signaling pathways,the active components of traditional Chinese medicine(such as flavonoids,anthraquinones,terpenoids)and traditional Chinese medicine compounds(such as Wuhu decoction,Pingchuan granule,Sanzi yangqin decoction)can inhibit airway inflammatory response,reduce airway hyperresponsiveness,and alleviate airway remodeling,thus playing a role in the treatment of asthma.However,most of the current studies are basic studies,and the quality of evidence is not high.In the future,high-quality clinical and basic studies should be further carried out to fully demonstrate the scientific nature of traditional Chinese medicine in the treatment of asthma by regulating autophagy.

关键词

支气管哮喘/自噬/中药活性成分/中药复方/研究进展

Key words

bronchial asthma/autophagy/active components of traditional Chinese medicine/traditional Chinese medicine compound/research progress

引用本文复制引用

基金项目

国家自然科学基金项目(82274578)

河南省中医药学科领军人才培养项目(豫卫中医函[2021]8号)

河南省"双一流"创建学科中医学科学研究专项(HSRP-DFCTCM-2023-3-05)

出版年

2024
中国药房
中国医院协会,中国药房杂志社

中国药房

CSTPCD北大核心
影响因子:0.956
ISSN:1001-0408
段落导航相关论文